| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yola Moride | |
| Anne-Marie Cloutier | |||
| Camille Craig | |||
| Inna Gridchyna | |||
| Lenhangmbong Nkeng | |||
| Sarah Frise | |||
| P2860 | cites work | Why don't physicians follow clinical practice guidelines? A framework for improvement | Q29619967 |
| Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data | Q31047942 | ||
| Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States | Q31107935 | ||
| Impact of FDA black box advisory on antipsychotic medication use | Q34092198 | ||
| Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters | Q34334572 | ||
| Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents | Q34582162 | ||
| Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. | Q34866473 | ||
| The impact of wording in "Dear doctor" letters and in black box labels | Q35032495 | ||
| Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes | Q35169462 | ||
| Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants | Q35896311 | ||
| Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program | Q35951667 | ||
| Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program | Q36129468 | ||
| Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programme | Q36433995 | ||
| Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults | Q36512651 | ||
| The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. | Q37112195 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects | Q37676950 | ||
| Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review | Q38019025 | ||
| Pediatric primary care providers and adolescent depression: a qualitative study of barriers to treatment and the effect of the black box warning | Q39794577 | ||
| Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. | Q41854298 | ||
| Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions | Q43202386 | ||
| Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs | Q43202669 | ||
| Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain | Q43265650 | ||
| Liver enzyme monitoring in patients treated with troglitazone | Q43702652 | ||
| Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation | Q43751216 | ||
| Coprescribing and codispensing of cisapride and contraindicated drugs | Q43755682 | ||
| Use of cisapride with contraindicated drugs in The Netherlands | Q43888420 | ||
| Practitioner acceptance of the dofetilide risk-management program | Q44098833 | ||
| Prescription drug monitoring programs and death rates from drug overdose | Q44336151 | ||
| Consumer understanding of prescription drug information: an illustration using an antidepressant medication | Q44336176 | ||
| Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: effective, but dissemination is challenging | Q44348249 | ||
| Impact of cisapride label changes on codispensing of contraindicated medications. | Q44481515 | ||
| Evaluation of the dofetilide risk-management program | Q44642217 | ||
| Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease | Q44814177 | ||
| Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone | Q45037773 | ||
| Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease. | Q45909246 | ||
| Pediatric prescribing practices and the FDA Black-box warning on antidepressants. | Q45926239 | ||
| Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. | Q46429199 | ||
| Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia | Q46507947 | ||
| Effects of Food and Drug Administration warnings on antidepressant use in a national sample | Q46818954 | ||
| Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. | Q46836809 | ||
| Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs | Q46911904 | ||
| Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? | Q46983480 | ||
| Integration of the recommendations of the Canadian Task Force on Preventive Health Care: obstacles perceived by a group of family physicians | Q47309880 | ||
| Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. | Q47947189 | ||
| Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs | Q50147822 | ||
| Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). | Q50542559 | ||
| Co-dispensing of contraindicated medications in patients using cisapride in Italy. | Q51805289 | ||
| Adherence to black box warnings for prescription medications in outpatients. | Q51819303 | ||
| Psychiatrists' attitudes about and informed consent practices for antipsychotics and tardive dyskinesia. | Q51940391 | ||
| Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects. | Q51972969 | ||
| P433 | issue | 6 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 572-579 | |
| P577 | publication date | 2014-02-24 | |
| P1433 | published in | Pharmacoepidemiology and Drug Safety | Q15759496 |
| P1476 | title | Methodological gaps in the assessment of risk minimization interventions: a systematic review | |
| P478 | volume | 23 |
| Q38874756 | A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. |
| Q52804934 | A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies. |
| Q34051864 | Advancing the field of pharmaceutical risk minimization through application of implementation science best practices |
| Q36342841 | Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data |
| Q47161547 | Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey. |
| Q38391532 | Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved |
| Q47653552 | Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations |
| Q47619604 | Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs |
| Q93371077 | Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register |
| Q50016764 | The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. |
Search more.